Vendor, Palo Alto, CA
Endpoint Health Inc.
UEI VXK3H62WKFM1, CAGE 8L2B3
1 award and $0 obligated between January 24, 2024 and April 18, 2024, 0% under full and open competition, against 100.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Competed Under SAP | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50122C00058Definitive Contract, January 24, 2024, Competed Under SAP, 100 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Endpoint: Gene Expression Scoring of Immune Activity Levels for Precision Use of Hydrocortisone in Septic Shock: Secondary Analysis of the ANAICS 541714, PSC AN13 | $0 |
- Places of performance
- California
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 2 across 1 awards